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INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel disease 
(IBD) with repeated cycles of remission and relapse.1 UC re-
quires life-long treatment both for induction and maintenance 
of remission.2-4 Corticosteroids are powerful medications that 
have been used for many years for the treatment of IBD. How-
ever, because of the toxicity profile of systemic steroids, clini-
cians often face challenges with using them for a longer term.
In recent years, new therapeutic agents for IBD have been in-
troduced with more favorable profiles in terms of safety and 
toxicity, compared to traditional steroids.5 Topically acting oral 
steroids are a group of drugs characterized by a low systemic 
bioavailability due to first-pass liver metabolism that minimizes 
the systemic concentration of the drug.6 Budesonide (BUD) 
and beclomethasone dipropionate (BDP) are two steroids with 
low bioavailability that have been studied in the treatment of 
IBD. The European Crohn’s and Colitis Organisation guidelines 
consider oral BUD as the first-choice drug for the treatment of 
mild-to-moderate Crohn’s disease confined to the ileocecal 
area.7 Commercially available oral preparations of BUD have 
release systems that deliver BUD specifically to the distal ileum 
and proximal colon.5 Therefore, if BUD is taken orally, its effica-
cy fades out in the proximal colon. The distal colonic and rectal 
lesions do not benefit from this drug. Unlike oral BUD formula-
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tions, BDP was formulated as an oral enteric coated compound 
to be released in the distal part of the small bowel and through-
out the colorectum owing to a combination of different meth-
acrylic polymers that protect the drug from the action of the 
gastric fluid and then dissolve at specific pH values, targeting 
colonic inflammatory diseases.8 Data on the efficacy of oral 
BDP in IBD are quite limited, compared to those for BUD.9
The efficacy of oral BDP in UC has been assessed in several 
clinical trials and observational studies. Based on acquired evi-
dence, BDP (5 mg/day) was recently released in Korea to treat 
mildly to moderately active UC. However, there have been no 
data regarding the efficacy of BDP in Korean patients with UC. 
Therefore, our aim was to evaluate the efficacy and safety of 
oral BDP in Korean patients with UC.
MATERIALS AND METHODS
Study design and definitions
This is a retrospective, single-center study that included 95 pa-
tients with active UC who were treated with oral BDP tablets (5 
mg/day) for 4 weeks. As endoscopy was not performed before 
and after BDP treatment in most of the patients, partial Mayo 
Clinic score (pMS; 0–9), the number of bowel movements (0–3), 
presence of blood in stools (0–3), and physician global assess-
ment (0–3) was calculated to determine the disease activity.10,11 
Disease activity was defined as mild (pMS<5), moderate (pMS 
5 to 7), and severe (pMS>7). After 4 weeks of therapy, clinical 
remission, clinical response, and response failure rates were 
evaluated. Clinical remission was defined as a post-treatment 
pMS of 0 or 1, clinical response as a decrease of two or three 
points in pMS and >30% from baseline, and response failure as 
a lack of clinical response. Also, we considered that clinical re-
mission was included in clinical response. Disease extension 
was classified as E1, E2, and E3 according to the Montreal Clas-
sification.12,13
Data regarding patient clinical characteristics, including dis-
ease duration and severity, concomitant therapies, and clinical 
outcomes were collected from reviewing the patients’ hospital 
chart. 
Patients undergoing treatment with 5-aminosalicylic acids 
(5-ASA) or sulfasalazine before the study were also included, 
and the use of these agents as concomitant treatments during 
the study period was permitted. Patients were excluded if they 
were on corticosteroids and were concomitantly diagnosed 
with severe cardiovascular, respiratory, hepatic or renal disease. 
Concurrent use of antidiarrheal drugs, topical mesalazine, and/
or topical steroids was allowed. The only drug that was not per-
mitted was a systemic oral or parenteral corticosteroid. Patients 
in whom pre-or post-treatment pMS could not be calculated 
were also excluded.
This study was performed in accordance with the Declara-
tion of Helsinki and was approved by Institutional Review 
Boards of Severance Hospital.
Statistical analysis
Qualitative variables are expressed using frequencies. Continu-
ous variables are expressed using mean±standard deviation. 
Fisher and chi-square tests were used to compare qualitative 
variables. Student’s t-test was used to compare quantitative 
variables. The associations between variables and remission 
rate were further examined in multivariate model using logistic 
regression analysis. All tests were two-tailed with a significance 
level set at p<0.05. Analyses were performed using IBM SPSS 
software version 20.0 (Armonk, NY, USA).
RESULTS
Patient characteristics and BDP treatment
The patients’ clinical characteristics are summarized in Table 1. 
There were 95 evaluable patients, 47 men and 48 women. Their 
median age was 44 years (range, 12–81 years). Eighty-five pa-
tients (89.5%) had left-sided or extensive colitis, with a median 
disease duration of 68 months (range, 3–300; 68.4±59.4 months). 
Ninety-one patients (95.8%) had mild to moderate disease ac-
tivity. All patients were on a maintenance therapy with oral or 
rectal 5-ASA compounds when the BDP therapy was started. 
For all patients, the BDP dose was 5 mg/day, which is the rec-
ommended regimen on the drug label.
Efficacy and safety of BDP
After 4 weeks of therapy, among the 95 patients, the clinical re-
mission and clinical response rate were 50.5% (48/95) and 
73.7% (70/95), respectively. Response failure was seen in 25 pa-
tients (26.3%) (Fig. 1). The mean change in pMS before and af-
ter receiving BDP therapy was 2.4 (±2.39) (p<0.001). In multi-
variate analysis, disease activity was the only factor associated 
with a favorable response (Table 2). Regardless of doses and 
types of 5-ASA, adding oral BDP was significantly effective in 
inducing clinical response or remission in Korean patients with 
UC (data not shown). The clinical remission rate was signifi-
cantly higher in the mild disease activity group (66.7%) than 
that in the moderate or severe disease activity group (41.9%) 
(p=0.024) (Fig. 2). There was no significant difference in remis-
sion rates according to disease extension in our study. More-
over, no significant side effects were reported. Patients that 
stopped taking BDP did so because of a lack of efficacy, but not 
because of side effects. There were 17 patients that required 
rescue treatment in our study. Systemic steroids were used as a 
rescue therapy in 11 patients after BDP treatment failed. The 
other 6 patients were treated with infliximab or adalimumab, 
which are used for moderate-to-severe UC.
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DISCUSSION
This is the first study reporting the efficacy and safety of oral 
BDP in Korean patients with active UC in clinical practice. In 
this study, more than 50% of the patients achieved clinical re-
mission, and two-thirds of them showed a clinical response af-
ter oral BDP (5 mg/day) treatment for 4 weeks. A previously 
published RECLICU study showed that the remission rate was 
significantly higher in mild and moderate disease activity group 
than that in severe disease activity group. Generally, an oral 
BDP medication is recommended for UC patients with mild to 
moderate disease activity, as disclosed in the drug label. In our 
study, there were 4 patients with severe disease activity who 
used oral BDP. Similarly, the clinical remission rate was signifi-
cantly higher in the mild disease activity group (66.7%) than 
that in the moderate or severe disease activity group (41.9%).
Unlike previous studies, in our study, all UC patients treated 
with BDP were included in the analysis to obtain more clinical 
and practical data on the efficacy and safety of oral BPD. UC 
patients in use of other concomitant medications and drug mod-
ification were not excluded at study inclusion. Patients with ad-
dition or dose increase of topical and/or oral 5-ASA were also 
included. The only drugs not permitted for concomitant use 
were systemic corticosteroids. All patients were on an oral 
5-ASA maintenance treatment when the BDP therapy was 
started. A retrospective study revealed that maintenance treat-
ment with thiopurine in UC patients was effective and safe.14,15 
There were 22 patients in this study who were concomitantly 
treated with azathioprine. Among the 22 patients, only 1 patient 
underwent BDP therapy with the addition of azathioprine. The 
other 21 patients were on a maintenance therapy of azathio-
prine when they started the oral BDP therapy. In subgroup 
analysis, there was no difference in clinical remission rates be-
tween the concomitant azathioprine use group and non-aza-
thioprine medication group. There was only one patient on inf-
liximab that started one day after BDP start. Thus, it might be 
possible that the use of concomitant medications contributes 
to clinical outcomes and increases he clinical remission and re-
sponse rates. In clinical practice, many clinicians use oral BDP 
with other drugs, therefore, the role of concomitant medica-
tions on the results can be taken into consideration.
Two randomized clinical trials compared the efficacies of 
BDP and 5-ASA.16,17 A 4-week, double-blind, placebo-controlled 
study demonstrated that oral BDP in combination with oral 
5-ASA was significantly more effective in achieving clinical re-
mission than 5-ASA alone in the treatment of patients with ex-
tensive or left-sided active UC.17 Subsequently, Campieri, et al.16 
compared the efficacy of oral BDP (5 mg) and 5-ASA (2.4 g) in a 
4-week multicenter, randomized, single-blind study. Oral BDP 
had an efficacy equivalent to that of 5-ASA in the treatment of 
left-sided and extensively mild-to-moderate UC. Moreover, pa-
tients with extensive UC were more likely to achieve a clinical 
and endoscopic improvement with oral BDP than with oral 
5-ASA alone.16 The proportion of patients who reached a 
4-week remission with oral BDP treatment was similar in both 
studies (58.6% and 63.0%, respectively).
Two studies, one prospective and one retrospective, evaluat-
ed the role and efficacy of BDP in clinical practice. The prospec-
tive study revealed that oral BDP therapy could be used instead 
of systemic corticosteroids in patients with mild-to-moderate 
Table 1. Baseline Characteristics of the Patients
Characteristics All patients (n=95)
Median age (range), yr 44 (12–81)
Gender
Male 47 (49.5)
Female 48 (50.5)
Azathioprine medication
Yes 22 (23.2)
No 73 (76.8)
Disease extension
Proctitis 10 (10.5)
Left-sided colitis 60 (63.2)
Extensive 25 (26.3)
Disease activity
Mild 33 (34.7)
Moderate 58 (61.1)
Severe 4 (4.2) 
Rescue therapy
Yes 17 (17.8)
Systemic steroids 11 (11.5)
Infliximab or adalimumab 6 (6.3)
No 78 (82.2)
ANCA  
Checked 74 (77.9)
Positive 26 (35.1)
Negative 48 (64.9)
Unchecked 21 (22.1)
Median disease duration (range), months 68 (3–300)
ANCA, anti-neutrophil cytoplasmic antibodies.
Values are presented as n (%) or median (range).
Fig. 1. Oral beclomethasone dipropionate efficacies after 4 weeks of 
treatment.
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UC who are not responding to 5-ASA and could be considered 
as a second-line treatment for these patients.18 The retrospec-
tive RECLICU study showed that oral BDP therapy induced a 
clinical response or remission in about two thirds of patients 
with active UC, with a remission rate of 44%. It had a good safe-
ty profile with mild adverse events in 434 patients. Remission 
rate was significantly higher in mild and moderate UC than in 
severe UC.19 Finally, Balzano, et al. compared the efficacy and 
safety of oral BDP and oral prednisone in mild to moderately 
active UC patients in an 8-week, multicenter, randomized, dou-
ble-blind study. This was the first randomized controlled study 
confirming that oral topical BDP was non-inferior to predniso-
lone in the treatment of active UC, with oral BDP presenting 
less steroid-related adverse effects.20
We elicited post-treatment outcomes from the data that were 
collected at 4 weeks after completing the oral BDP therapy. We 
evaluated the pMSs at both 4 weeks and 8 weeks after the oral 
BDP treatment. After 4 weeks, clinical remission and clinical re-
sponse rates were 50.5% and 73.7%, respectively. After 8 weeks, 
excluding the 9 patients who underwent rescue treatment at 4 
weeks, the clinical remission and response rates for 86 patients 
were 63.9% and 70.9%, respectively. With continued use of 5-ASA 
and azathioprine, clinical remission could be achieved at 1 
month after completing the oral BDP treatment. There were 17 
patients who achieved clinical remission at 8 weeks, with par-
tial clinical response or failure at 4 weeks. Thus, evaluating clini-
cal outcomes at only 4 weeks is not recommended, as a clinical 
remission could be achieved slowly, even after discontinuing 
oral BDP.
There are some limitations to our study. First, there were no 
data in our study regarding the long-term treatment outcomes 
without the use of systemic corticosteroids. In a previously pub-
lished single-center study, Papi, et al.18 found a remission rate of 
Table 2. Univariate and Multivariate Analysis of Factors Predictive of a Clinical Remission
Variables
Remission 
(n=48, %)
Not remission 
(n=47, %)
Type of analysis
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Age (yr)
Median (range) 45.1 (17–81) 43.7 (12–75) 0.714 1.002 (0.973–1.032) 0.906
Gender
Male/female 21/27 (43.8/56.2) 26/21 (55.3/44.7) 0.388 0.710 (0.278–1.813) 0.474
Azathioprine medication
Yes/no 12/36 (25.0/75.0) 10/37 (21.3/78.7) 0.667 0.878 (0.308–2.502) 0.807
Disease extension
Proctitis 6 4 1 1
Left-sided colitis 14 11 1.71 (0.439–6.699) 0.438 2.669 (0.523–13.634) 0.238
Extensive 28 32 1.18 (0.265–5.237) 0.829 1.848 (0.384–8.889) 0.444
ANCA 
Positive 10 (29.4) 16 (40) 1.60 (0.605–4.228) 0.343
Negative 24 (70.6) 24 (60) 1
Unknown 14 7
Disease duration (months)
Median (range) 78.17 (4–300) 58.34 (3–204) 0.109
4 week treatment effect
Disease activity
Mild/moderate 22/25 11/33 2.64 (1.083–6.435) 0.033 2.64 (1.083–6.435) 0.033
Mild/moderate+severe 22/26 11/36 2.77 (1.146–6.691) 0.024 2.64 (1.083–6.435) 0.033
Mild/severe 22/1 11/3 2.45 (0.747–8.036) 0.139
Moderate/severe 25/1 33/3 2.27 (0.223–23.174) 0.488
Mild+moderate/severe 47/1 44/3 3.21 (0.321–31.970) 0.321
ANCA, anti-neutrophil cytoplasmic antibodies.
Fig. 2. Oral beclomethasone dipropionate treatment outcomes according 
to disease activity.
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75%, with more than 50% of the UC patients maintaining 1-year 
remission, with no further need of steroid treatment after the 
initial dose of 10 mg/day for 4 weeks and 5 mg/day for an addi-
tional 4 weeks. Second, as a retrospective study, there were only 
16 patients that underwent endoscopy at the beginning of the 
oral BDP therapy.21 The aim of this study was to evaluate the ef-
ficacy and safety of oral BDP in Korean patients with UC in clin-
ical practice. In this setting, endoscopy was not routinely per-
formed. Third, in this study design, there was no control group. 
BDP is usually used concurrently with 5-ASA for remission in-
duction. In our study, oral BDP was used in combination with 
5-ASA for remission induction in all patients. Therefore, we were 
not able to compare the efficacy between with BDP and with-
out BDP groups, and could not address the benefits of adding 
BDP in patients with mild disease activity UC having a generally 
favorable disease course. However, for remission induction, cli-
nicians often face challenges while using systemic steroids for a 
long term because of the toxicity profile of systemic steroids. 
Oral BDP is a group of drugs that minimizes the systemic con-
centration of the drug with more favorable profiles, in terms of 
safety and toxicity, compared to traditional steroids. We think 
that here in lies the meaning of using oral BDP. In our study, 
BDP was efficacious in inducing a clinical response or remis-
sion in Korean patients with UC refractory to 5-ASA. More ran-
domized control studies are needed to confirm the efficacy and 
safety of the drug.
In conclusion, oral BDP (5 mg/day for 4 weeks) was effica-
cious in inducing a clinical response or remission in Korean pa-
tients with UC. Patients with mild UC were more likely to in-
duce remission than those with moderate or severe UC, after 
receiving the BDP treatment for 4 weeks. BDP had a good safety 
profile in these patients.
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